Senicapoc in Patients With Worsening Fibrotic Interstitial Lung Disease

This study will investigate whether the senicapoc drug can prevent the scarring from worsening in interstitial lung disease. Researchers will compare Senicapoc to a placebo (a look-alike substance that contains no drug) to see if Senicapoc works to prevent lung function worsening. Participants will be asked to take 3 tablets a day for 26 weeks. Within this period, doctors will follow the participants, ask for experience of adverse events, check lung function and organ status, and participants will need to fill out quality-of-life questionnaires. A total of 5 visits are required, at initiation, after4, 13, 26 and 52 weeks. The final visit will occur 52 weeks after initiation and consist of a normal visit in the outpatient clinic where the doctor asks for relevant information regarding the period after end of administration of the study drug.

NCT Number	NCT06714123
Lead Sponsor	Vejle Hospital Collaborators: Odense Patient Data Explorative Network
Conditions	Pulmonary Fibrosis, Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
Enrollment	140 participants
Start Date	2025-08-01
Primary Completion	2028-12 (estimated)
Study Completion	2028-12 (estimated)
Updated on ClinicalTrials.gov	2026-05-07